Is Neil Woodford Right? Should GlaxoSmithKline plc Be Broken Up?

Would GlaxoSmithKline plc (LON: GSK) perform better if it were carved-up into separate companies?

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Neil Woodford is perhaps the most respected British fund manager of his generation. His record is remarkable, considering that most of his investing wins have been achieved during the post-millennial bear market.

So when he says GlaxoSmithKline (LSE: GSK) should be broken up, people sit up and listen. But is he right?

What a carve-up!

Well, let’s dig a little deeper. I have said in previous articles that Big Pharma’s future is more complex than you think. To be successful in the drugs industry, you need to fight a battle on several fronts, developing chemical drugs, blockbuster biological drugs, over-the-counter medicines, and expanding into emerging markets.

So, in principle, you could break GlaxoSmithKline up. Woodford has talked about four separate companies. Perhaps you could have a company based on patent-expired, low-cost medicines, competing with the likes of Israeli generics manufacturer Teva. You could also have a business focussed on branded, healthcare consumer goods, run along the lines of a Reckitt Benckiser.

The bulk of GSK would take the form of a research-intensive firm with the aim of selling the next drugs blockbuster, say like AstraZeneca. Finally, you would have a company that expands into countries such as Brazil and India, selling low-cost, effective medicines tailored to individual markets. A sort of Hutchison China Meditech.

It seems an attractive idea, but I’m not sure it would yield much value for increasingly impatient GlaxoSmithKline shareholders. I just wonder if this is the type of reflex reaction that most fund managers have when one of their main investments under-performs. Neil Woodford is one of the Big Pharma’s strongest backers, and has poured money into Glaxo, but with little return as yet.

If your investment isn’t broke, then don’t fix it. But if it is doing badly, maybe something does need to change.

The ties that bind

Yet I see a common strand that runs through this company, and which should be enough to bind GSK together. That strand is research. Whether you are developing a generic formulation tailored to an emerging market, a new cold remedy to be sold over the counter, or a high-margin, expensive anti-cancer treatment to compete with the likes of Herceptin, you need to innovate.

This research can take many different forms, and involve a range of expertises, but it is innovation all the same. 

I still believe GlaxoSmithKline can perform well, but it has many challenges ahead of it, including the increasingly crowded pharmaceutical marketplace and the growing popularity of generics. But it has to keep on trying.

In my mind, it is not about changing what it is doing. Instead, it is about doing it better.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Prabhat Sakya has no position in any shares mentioned. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Affectionate Asian senior mother and daughter using smartphone together at home, smiling joyfully
Investing Articles

How I’d invest my first £20k ISA to target £4,900 a year from dividend shares

Looking for dividend shares in a new Stocks and Shares ISA, and want diversification too? Here's how I'd go about…

Read more »

Passive income text with pin graph chart on business table
Investing Articles

Yields of up to 7%! I’d consider boosting my income with these FTSE dividend stocks

The London market has some decent-looking dividend stocks right now, and I’m tempted by these two for growing income streams.

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

I’d put £20K in an ISA now to target a £1,900 monthly second income in future!

Christopher Ruane shares why he thinks a long-term approach to investing and careful selection of shares could help him build…

Read more »

Mature couple at the beach
Investing Articles

6 stocks that Fools have been buying!

Our Foolish freelancers are putting their money where their mouths are and buying these stocks in recent weeks.

Read more »

Black woman using loudspeaker to be heard
Investing Articles

I was right about the Barclays share price! Here’s what I think happens next

Jon Smith explains why he still feels the Barclays share price is undervalued and flags up why updates on its…

Read more »

Investing Articles

Where I’d start investing £8,000 in April 2024

Writer Ben McPoland highlights two areas of the stock market that he would target if he were to start investing…

Read more »

View of Tower Bridge in Autumn
Investing Articles

Ahead of the ISA deadline, here are 3 FTSE 100 stocks I’d consider

Jon Smith notes down some FTSE 100 stocks in sectors ranging from property to retail that he thinks could offer…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

Why I think Rolls-Royce shares will pay a dividend in 2024

Stephen Wright thinks Rolls-Royce shares are about to pay a dividend again. But he isn’t convinced this is something investors…

Read more »